Hypherdata

Name: Hypherdata
Brand: Hypherdata

License real-world data from Healthcare Data Providers across continents, data modalities, and medical areas.

Est 2019|Valuation $4.6M|Raised $120K

LinkedIn 2K|Website|FTEs 5|HQ Amsterdam, North Holland, NL

MarketsSource-to-Contract eSourcing

Published Jul 15, 2026

01Common complaints

Hypherdata may be a poor fit when: 1. You require extensive independent validation and numerous third‑party reviews before purchase; public independent reviews are limited. 2. You require guaranteed, standardized "ready‑to‑analyze" datasets with comprehensive documentation and repeatability; a matchmaking/auction model can yield heterogeneous dataset outputs. 3. Your procurement depends on specific certifications (for example, SOC 2 Type II) and the vendor cannot demonstrate them. 4. Your use case is dependent on US‑only networks and large-scale identity resolution where established US incumbents may offer more extensive local connectivity. 5. Budget limitations make a platform fee plus data licensing and professional services more expensive than direct or DIY sourcing for simple datasets.

Deal disqualifiers

Requirement for publicly documented security certifications that the vendor cannot provide under NDA or otherwise
Need for a product with extensive independent third‑party reviews prior to purchase
Highly sensitive use cases demanding certified clean-room or similarly regulated controls that are not documented publicly

Vendor-acknowledged limitations

No explicit public "known issues" list or public roadmap was located in accessible official materials during this research.

Practical limitations inferred from available evidence

Limited public transparency into security controls and certifications.
Limited independent customer review coverage, complicating third‑party risk assessment.
Ambiguity in company HQ and legal address across public databases, which has implications for contracting and compliance.

02Why they buy

Vendor-stated unique selling points

Reverse data auction: The vendor describes a competitive bidding mechanism for data providers to respond to buyer requests.
Procurement workflow centralization: The vendor describes tools for request posting, bid management, standardized agreements, study tracking, and payments.

Where competitors may have stronger positioning

Competitors often emphasize larger network scale and more detailed provenance or identity-resolution capabilities, which may be advantageous depending on the buyer's requirements.

03Field reports

Review-platform presence (G2 / TrustRadius / Gartner Peer Insights)

Searches did not surface accessible product review pages for Hypherdata on mainstream review platforms during this research.

Community/social proof

Public community discussion and independent reviews appear limited. Some public posts reflect hiring activity rather than product reviews.

What exists publicly instead of user reviews

The company publishes vendor-authored use-case narratives and platform examples (for example, Phase 3 oncology and cardiovascular RWE scenarios and AI training dataset examples). These are vendor-provided materials rather than independent customer reviews.

Implications of limited independent reviews

Procurement risk: limited third‑party feedback reduces available signals on reliability, implementation effort, and support quality.
Reference checks: buyers should request customer references (ideally in the same region and with similar data modalities) and validate time-to-contract, data quality, and delivery SLAs.

Vendor-authored use cases (examples)

The vendor publishes several use-case categories and high-level descriptions, including: - Comparative effectiveness data for a Phase 3 cardiovascular study. - Efficacy and safety datasets for an oncology Phase 3 trial. - Longitudinal cancer progression datasets and patient journey mapping. - AI training datasets combining imaging and EHR/EMR data. These descriptions generally do not include named customers, timelines, itemized cost savings, delivered sample sizes and completeness, or specific data quality metrics (for example, missingness rates or representativeness assessments).

Critical evaluation

- Strength: The use cases indicate the vendor has designed workflows that map to common pharma/RWE study requirements, including cohort criteria and study-level specifications. - Limitation: The lack of measurable outcomes, independent validation, and detailed delivery metrics makes it difficult to assess realized ROI. Buyers should request anonymized statements of work, delivery SLA metrics, data quality acceptance criteria, and examples of delayed or failed studies and root-cause analyses.

04Best fit

Company sizes

Likely fits:

Startups to mid-market health AI and medtech firms that require specialized datasets but lack large internal data‑sourcing teams.
Enterprise pharmaceutical and life sciences organizations running RWE programs that can standardize procurement workflows.

Exact contract minimums, employee counts, and published pricing bands are not publicly available; buyers should confirm these details during vendor discussions.

Industries / verticals

Pharmaceutical RWE, HEOR, and medical affairs
Healthcare AI (imaging plus EHR/EMR use cases)

Roles and personas

RWE leads, HEOR directors, and medical affairs analytics teams
Data procurement and vendor management teams
Data science and ML leads requiring cohort-specific datasets
Legal, privacy, and vendor risk teams

Pain points addressed

Administrative and timeline overhead for identifying data holders and negotiating contracts
Limited visibility into available providers and dataset coverage
Fragmented study management practices (email, spreadsheets, and manual tracking)

05The pitch

What the product does (core value proposition)

Hypherdata describes itself as a B2B "reverse data auction" marketplace for healthcare real‑world data (RWD). The platform enables data consumers (for example, pharmaceutical companies and startups) to post data study requests and allows data providers (for example, hospitals and research institutions) to submit competitive bids to fulfill those requests. The vendor states the platform centralizes workflows (requests, bids, contracting, payments, study management) with the objective of reducing time and administrative effort in sourcing, contracting, and managing RWD studies. Key product concepts described by the vendor: - Reverse RWD auction / competitive bidding intended to influence pricing through provider bids. - A provider network that the vendor describes as vetted across multiple regions and medical specialties. - Standardized licensing agreements intended to reduce repeated contract negotiations. - Mentions of escrow and data exchange vaults and role-based access controls, though technical and implementation details are not publicly documented.

Target market and market positioning

Hypherdata targets: - Life sciences and pharmaceutical teams conducting real‑world evidence (RWE) work, including clinical development, medical affairs, HEOR, and post‑market surveillance. - Health AI companies and organizations building machine learning models that require retrospective datasets (imaging, EMR/EHR, labs, omics). The vendor presents its primary differentiator as a reverse auction plus matchmaking workflow rather than a traditional storage or simple listing marketplace; this positioning is framed by the company as a way to support procurement workflows.

Get a comprehensive analysis of Hypherdata including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Jul 15, 2026

01Common complaints

Hypherdata may be a poor fit when:

You require extensive independent validation and numerous third‑party reviews before purchase; public independent reviews are limited.
You require guaranteed, standardized "ready‑to‑analyze" datasets with comprehensive documentation and repeatability; a matchmaking/auction model can yield heterogeneous dataset outputs.
Your procurement depends on specific certifications (for example, SOC 2 Type II) and the vendor cannot demonstrate them.
Your use case is dependent on US‑only networks and large-scale identity resolution where established US incumbents may offer more extensive local connectivity.
Budget limitations make a platform fee plus data licensing and professional services more expensive than direct or DIY sourcing for simple datasets.

Deal disqualifiers

Requirement for publicly documented security certifications that the vendor cannot provide under NDA or otherwise
Need for a product with extensive independent third‑party reviews prior to purchase
Highly sensitive use cases demanding certified clean-room or similarly regulated controls that are not documented publicly

Vendor-acknowledged limitations

No explicit public "known issues" list or public roadmap was located in accessible official materials during this research.

Practical limitations inferred from available evidence

Limited public transparency into security controls and certifications.
Limited independent customer review coverage, complicating third‑party risk assessment.
Ambiguity in company HQ and legal address across public databases, which has implications for contracting and compliance.

02Why they buy

Vendor-stated unique selling points

Reverse data auction: The vendor describes a competitive bidding mechanism for data providers to respond to buyer requests.
Procurement workflow centralization: The vendor describes tools for request posting, bid management, standardized agreements, study tracking, and payments.

Where competitors may have stronger positioning

Competitors often emphasize larger network scale and more detailed provenance or identity-resolution capabilities, which may be advantageous depending on the buyer's requirements.

03Field reports

Review-platform presence (G2 / TrustRadius / Gartner Peer Insights)

Searches did not surface accessible product review pages for Hypherdata on mainstream review platforms during this research.

Community/social proof

Public community discussion and independent reviews appear limited. Some public posts reflect hiring activity rather than product reviews.

What exists publicly instead of user reviews

Implications of limited independent reviews

Procurement risk: limited third‑party feedback reduces available signals on reliability, implementation effort, and support quality.
Reference checks: buyers should request customer references (ideally in the same region and with similar data modalities) and validate time-to-contract, data quality, and delivery SLAs.

Vendor-authored use cases (examples)

The vendor publishes several use-case categories and high-level descriptions, including:

Comparative effectiveness data for a Phase 3 cardiovascular study.
Efficacy and safety datasets for an oncology Phase 3 trial.
Longitudinal cancer progression datasets and patient journey mapping.
AI training datasets combining imaging and EHR/EMR data.

These descriptions generally do not include named customers, timelines, itemized cost savings, delivered sample sizes and completeness, or specific data quality metrics (for example, missingness rates or representativeness assessments).

Critical evaluation

Strength: The use cases indicate the vendor has designed workflows that map to common pharma/RWE study requirements, including cohort criteria and study-level specifications.
Limitation: The lack of measurable outcomes, independent validation, and detailed delivery metrics makes it difficult to assess realized ROI. Buyers should request anonymized statements of work, delivery SLA metrics, data quality acceptance criteria, and examples of delayed or failed studies and root-cause analyses.

04Best fit

Company sizes

Likely fits:

Startups to mid-market health AI and medtech firms that require specialized datasets but lack large internal data‑sourcing teams.
Enterprise pharmaceutical and life sciences organizations running RWE programs that can standardize procurement workflows.

Exact contract minimums, employee counts, and published pricing bands are not publicly available; buyers should confirm these details during vendor discussions.

Industries / verticals

Pharmaceutical RWE, HEOR, and medical affairs
Healthcare AI (imaging plus EHR/EMR use cases)

Roles and personas

RWE leads, HEOR directors, and medical affairs analytics teams
Data procurement and vendor management teams
Data science and ML leads requiring cohort-specific datasets
Legal, privacy, and vendor risk teams

Pain points addressed

Administrative and timeline overhead for identifying data holders and negotiating contracts
Limited visibility into available providers and dataset coverage
Fragmented study management practices (email, spreadsheets, and manual tracking)

05The pitch

What the product does (core value proposition)

Key product concepts described by the vendor:

Reverse RWD auction / competitive bidding intended to influence pricing through provider bids.
A provider network that the vendor describes as vetted across multiple regions and medical specialties.
Standardized licensing agreements intended to reduce repeated contract negotiations.
Mentions of escrow and data exchange vaults and role-based access controls, though technical and implementation details are not publicly documented.

Target market and market positioning

Hypherdata targets:

Life sciences and pharmaceutical teams conducting real‑world evidence (RWE) work, including clinical development, medical affairs, HEOR, and post‑market surveillance.
Health AI companies and organizations building machine learning models that require retrospective datasets (imaging, EMR/EHR, labs, omics).

The vendor presents its primary differentiator as a reverse auction plus matchmaking workflow rather than a traditional storage or simple listing marketplace; this positioning is framed by the company as a way to support procurement workflows.

Get a comprehensive analysis of Hypherdata including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →